List of Excipients in Branded Drug FOSPHENYTOIN SODIUM

Generic Drugs Containing FOSPHENYTOIN SODIUM

Company	Ingredient	NDC	Excipient
West-Ward Pharmaceuticals Corp	fosphenytoin sodium	0143-9788	HYDROCHLORIC ACID
West-Ward Pharmaceuticals Corp	fosphenytoin sodium	0143-9788	SODIUM HYDROXIDE
West-Ward Pharmaceuticals Corp	fosphenytoin sodium	0143-9788	TROMETHAMINE

What are the Most Frequently-Used Excipients in FOSPHENYTOIN SODIUM?

# Of NDCs	Excipient
11	HYDROCHLORIC ACID
11	SODIUM HYDROXIDE
11	TROMETHAMINE

Fosphenytoin Sodium Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

Fosphenytoin sodium is an injectable phenytoin prodrug used when intravenous or intramuscular administration is required for seizure management, including status epilepticus. Its principal formulation advantage is the elimination of phenytoin injection’s propylene glycol and ethanol vehicle. The commercial opportunity is therefore concentrated in ready-to-use, dilution-stable, preservative-free hospital products with reliable supply, flexible packaging, and reduced administration burden.

The highest-value development paths are generic or differentiated injectable products that preserve fosphenytoin’s established excipient profile while improving presentation, stability, pharmacy workflow, and shortage resilience.

What excipients are used in fosphenytoin sodium injection?

The reference product, Cerebyx, uses tromethamine as the principal buffering excipient, with hydrochloric acid and sodium hydroxide for pH adjustment and water for injection as the vehicle. The formulation is alkaline, with a labeled pH of approximately 8.6 to 9.2. The product is supplied as fosphenytoin sodium equivalent to 50 mg phenytoin sodium equivalents, or 50 mg PE, per mL.[1]

Formulation element	Commercial function	Development implication
Fosphenytoin sodium	Water-soluble prodrug of phenytoin	Label strength is expressed in phenytoin equivalents
Tromethamine	Buffering and pH control	Key component for solubility and chemical stability
Hydrochloric acid	pH adjustment	Must be controlled within the product’s alkaline target
Sodium hydroxide	pH adjustment	Supports final pH and batch consistency
Water for injection	Sterile vehicle	Requires parenteral-grade quality and endotoxin control

Fosphenytoin was designed to provide a more soluble injectable form of phenytoin. The prodrug can be administered intravenously or intramuscularly, while phenytoin sodium injection has historically been associated with vehicle-related tolerability and administration limitations.[1,2]

How does the fosphenytoin excipient system affect product performance?

The excipient system controls solubility, pH, dilution compatibility, precipitation risk, and container compatibility. Tromethamine is commercially important because the formulation must remain sufficiently soluble at a high drug load while avoiding precipitation after dilution or contact with infusion systems.

The principal formulation risks are:

1. pH drift: Changes in buffer capacity or adjustment strategy can alter solubility and degradation.
2. Dilution instability: The product must remain suitable for approved dilution conditions, including compatible intravenous fluids.
3. Precipitation: Local concentration changes can create particles when the product is mixed improperly or exposed to incompatible conditions.
4. Container interaction: High-pH solutions can interact with elastomeric closures, glass surfaces, or plastic infusion components.
5. Particulate formation: Injectable products require tight control of visible and subvisible particles.
6. Assay conversion errors: Dosing must be calculated in phenytoin equivalents rather than the mass of fosphenytoin sodium.

A formulation program should establish pH, osmolality, buffer concentration, drug concentration, dilution behavior, and hold-time performance as linked critical quality attributes. Excipient changes should be assessed against precipitation, degradation, extractables, leachables, and administration-device compatibility.

What formulation opportunities exist for fosphenytoin sodium?

The strongest opportunities are improvements in presentation rather than major changes to the chemical excipient system.

Ready-to-use and pharmacy-ready presentations

A ready-to-administer or ready-to-dilute product can reduce compounding steps in emergency departments, intensive-care units, operating rooms, and inpatient pharmacies. Commercial formats may include:

• Single-dose vials in multiple fill volumes
• Unit-dose syringes for emergency use
• Pharmacy-ready infusion bags
• Standardized concentrations for institutional protocols
• Small-volume presentations for pediatric or weight-based dosing
• Larger-volume presentations for adult loading doses

A prefilled syringe would require extensive compatibility and extractables work because the alkaline formulation may interact differently with syringe barrels, plungers, lubricants, and needle assemblies than with conventional vial components.

Preservative-free products

Preservative-free, single-dose packaging is the most defensible hospital-market position. It aligns with acute-care use and avoids introducing antimicrobial preservatives into a product intended for intravenous or intramuscular administration. Multi-dose packaging would create additional sterility, preservative efficacy, and in-use stability requirements with limited commercial benefit.

Improved dilution and hold-time performance

A differentiated product could support longer validated hold times after dilution, subject to FDA-approved labeling. This may reduce medication waste and improve pharmacy workflow. The value depends on demonstrated chemical stability, sterility assurance, particulate control, and compatibility with common infusion containers.

Device-compatible presentations

Hospitals increasingly use automated dispensing systems, bar-code medication administration, closed-system transfer devices, and smart pumps. A product designed for standardized bar coding, clear concentration labeling, and compatibility with common administration sets can gain formulary preference without changing the active ingredient.

Which excipient changes are feasible under the FDA generic pathway?

A 505(j) abbreviated new drug application generally requires the proposed product to match the reference product in dosage form, strength, route of administration, and other relevant characteristics. An ANDA applicant may use different inactive ingredients if the differences are permissible and do not affect safety, efficacy, quality, or performance.[3]

For fosphenytoin sodium injection, the lowest regulatory-risk strategy is to retain the reference product’s core excipient architecture:

• Tromethamine as the buffer
• Water for injection as the vehicle
• Hydrochloric acid and sodium hydroxide for pH adjustment
• No unnecessary preservative
• No propylene glycol or ethanol vehicle

A different buffer, surfactant, chelator, tonicity agent, or antioxidant could trigger additional justification. The applicant would need to show that the change does not affect pH, solubility, degradation, dilution compatibility, particulate levels, or clinical administration.

The FDA Inactive Ingredient Database can support precedent analysis, but database presence does not eliminate the need to justify concentration, route, dosage form, and product-specific safety.[4]

What patents protect fosphenytoin sodium products?

The original fosphenytoin compound and formulation patent estate is mature. Commercial exclusivity is primarily controlled by generic competition, regulatory requirements, manufacturing capability, and hospital contracting rather than by a new active-ingredient patent position.

IP category	Relevance to fosphenytoin sodium	Commercial assessment
Original compound patents	Covered fosphenytoin chemistry and prodrug use	Historical protection is expected to have expired
Reference formulation patents	May have covered soluble injectable formulations	Any remaining enforceability requires claim-by-claim review
Method-of-use patents	Could address seizure treatment or dosing	Limited value where uses are established and labeled
Manufacturing patents	May cover synthesis, purification, or sterile processing	Potential barrier if claims remain enforceable
Packaging or device patents	Could cover syringes, bags, or administration systems	More relevant to differentiated products
Orange Book-listed patents	Control certain ANDA Paragraph IV procedures	Must be checked against the current FDA listing

The FDA Orange Book is the controlling source for patents listed against an approved reference product. Patent numbers, expiration dates, and any litigation-related status should be verified in the current Orange Book entry for the applicable fosphenytoin sodium reference product.[5]

When does fosphenytoin sodium lose exclusivity?

Fosphenytoin sodium has already passed the period of meaningful new-chemical-entity exclusivity associated with its original approval. The commercial question is therefore not when the molecule first loses exclusivity, but whether any listed patents, pediatric exclusivity, regulatory exclusivity, or product-specific litigation can delay a particular ANDA launch.

Exclusivity type	Relevance
New chemical entity exclusivity	Expired for this mature product
Five-year orphan exclusivity	Not the standard basis for fosphenytoin commercial protection
Three-year clinical-investigation exclusivity	Depends on later qualifying changes, not the original product
Pediatric exclusivity	Temporary and product-specific
Patent protection	Depends on current Orange Book listings
180-day generic exclusivity	May affect the first substantially complete Paragraph IV filer
Biosimilar exclusivity	Not applicable because fosphenytoin is a small-molecule drug

Are there Paragraph IV challenges to fosphenytoin sodium?

Any Paragraph IV risk must be assessed against the current Orange Book listing and FDA approval history. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. The reference sponsor may file patent litigation within the statutory period, potentially triggering a 30-month stay of ANDA approval under the Hatch-Waxman framework.[6]

For a mature injectable product, the key diligence points are:

• Whether the reference product has active Orange Book-listed patents
• Whether any listed patent covers the formulation or only a narrow use
• Whether an ANDA applicant has filed a Paragraph IV certification
• Whether a 30-month stay has been triggered
• Whether a settlement agreement restricts generic launch
• Whether the first-filer position has commercial value

Patent risk is likely to be lower than manufacturing and supply risk if no active formulation or process patent remains listed. A product can still face launch delays from facility readiness, inspection findings, sterile manufacturing capacity, or unresolved quality deficiencies.

What patent litigation affects fosphenytoin sodium?

Patent litigation should be separated from product-liability, antitrust, supply, and regulatory disputes. For fosphenytoin, the commercially relevant litigation questions are:

1. Whether an active Orange Book patent is asserted against an ANDA.
2. Whether a settlement includes a delayed generic-launch date.
3. Whether the settlement contains authorized-generic or supply provisions.
4. Whether a court decision affects formulation, process, or use claims.
5. Whether regulatory exclusivity remains during the proposed launch window.

No biosimilar litigation pathway applies. Fosphenytoin is a chemically synthesized small molecule, so competitors file ANDAs rather than abbreviated biologics applications.

Which companies compete in fosphenytoin sodium?

The market includes the reference sponsor and generic injectable manufacturers with sterile fill-finish capacity. FDA-approved product listings and current supply records should be used to identify active manufacturers, discontinued products, and available strengths.[5,7]

Competition is shaped by:

• FDA approval status
• Number of active suppliers
• Institutional contracts
• Wholesale acquisition cost and contract discounts
• Back-order history
• Manufacturing-site reliability
• Availability of multiple vial sizes
• Ability to support emergency and bulk hospital demand

A manufacturer with only one sterile facility may have a weaker commercial position than a company with redundant sites, even if the product is approved. Hospital buyers often value continuity of supply more than modest formulation differences.

What FDA regulatory status applies to fosphenytoin sodium?

Fosphenytoin sodium injection is regulated as a prescription drug under an NDA or ANDA pathway. An ANDA product must demonstrate pharmaceutical equivalence and bioequivalence, with injectable products generally benefiting from the direct-to-systemic nature of parenteral administration. The applicant must still establish quality, sterility, container-closure integrity, stability, labeling, and manufacturing compliance.[3]

FDA review will focus heavily on:

• Sterile manufacturing controls
• Endotoxin and sterility testing
• Visible and subvisible particulate matter
• Assay and related substances
• pH and osmolality
• Dilution compatibility
• Container-closure integrity
• Extractables and leachables
• Stability after preparation and dilution
• Correct use of phenytoin-equivalent labeling

How strong is the fosphenytoin sodium patent estate?

The estate is likely weak as a barrier to conventional generic entry because the product is mature and the key therapeutic and formulation concepts are established. Patent strength may remain meaningful in narrower areas:

• Specialized prefilled delivery systems
• Ready-to-use infusion products
• Novel container materials
• Improved stability claims
• Manufacturing processes with measurable purity advantages
• New administration protocols supported by qualifying clinical data

A new excipient combination alone is unlikely to create durable protection unless it produces an unexpected technical effect and supports patentable claims with credible comparative data.

What commercial opportunities exist in fosphenytoin sodium?

The opportunity is a hospital injectable platform rather than a premium branded medicine.

Opportunity	Revenue logic	Main barrier
Authorized generic or conventional ANDA	Base-volume hospital sales	Price erosion and contract competition
Shortage-resilient supply	Premium for reliable availability	Sterile manufacturing capacity
Prefilled emergency syringe	Workflow and administration value	Device compatibility and higher COGS
Ready-to-use infusion bag	Reduced pharmacy preparation	Stability and packaging validation
Pediatric-oriented vial sizes	Reduced waste and dosing flexibility	Smaller addressable volume
Dual-source institutional contracts	Supply assurance	Need for redundant production
International injectable expansion	Geographic diversification	Country-specific registration and tender pricing

Public companies generally do not disclose fosphenytoin revenue separately. Revenue exposure should be estimated using unit volume, hospital share, average net price, contract discounts, and shortage-adjusted demand rather than relying on total company sales.

How does fosphenytoin sodium compare with phenytoin sodium injection?

Fosphenytoin has a more favorable injectable formulation profile because it is water-soluble and does not rely on the propylene glycol and ethanol vehicle associated with conventional phenytoin sodium injection. Fosphenytoin can be administered intramuscularly, while phenytoin sodium injection is primarily used intravenously when rapid parenteral therapy is required.[1,2]

Attribute	Fosphenytoin sodium	Phenytoin sodium injection
Chemical form	Water-soluble prodrug	Poorly soluble active drug salt
Common vehicle concern	No propylene glycol/ethanol vehicle	Vehicle-related tolerability and compatibility concerns
Administration	Intravenous or intramuscular	Primarily intravenous in acute use
Dose expression	Phenytoin equivalents	Phenytoin sodium or phenytoin dosing convention
Formulation opportunity	Packaging, dilution, workflow	Solubility and vehicle limitations
Generic differentiation	Supply and delivery format	Vehicle, concentration, and administration profile

What generic launch risks exist?

The leading launch risks are operational:

• Inability to secure reliable sterile fill-finish capacity
• Batch failures linked to pH or particulate matter
• Container-closure incompatibility
• Limited access to tromethamine or qualified suppliers
• Inadequate dilution or in-use stability data
• Hospital reluctance to switch emergency-use products
• Contract pricing below sustainable margins
• Concurrent entry by several ANDA applicants
• Product-specific FDA inspection or quality issues

The best launch strategy is a conservative formulation, multiple qualified excipient suppliers, redundant manufacturing capacity, and packaging designed for emergency-care inventory systems.

Key Takeaways

• Tromethamine, water for injection, hydrochloric acid, and sodium hydroxide define the established fosphenytoin sodium injection formulation.
• The strongest formulation strategy is to preserve the proven excipient system and differentiate through packaging, stability, and pharmacy workflow.
• Fosphenytoin is a small-molecule drug; biosimilar risk does not apply.
• Original molecule exclusivity is no longer the primary commercial barrier.
• Current Orange Book listings and any Paragraph IV litigation must be checked before launch or licensing decisions.
• The most credible commercial opportunities are preservative-free vials, prefilled syringes, ready-to-use bags, and shortage-resilient hospital supply.
• Manufacturing reliability, sterile capacity, and contracting are likely to matter more than broad composition-of-matter patent protection.

FAQs About Fosphenytoin Sodium Excipient and Patent Strategy

Can tromethamine be replaced in a fosphenytoin sodium generic?

Potentially, but replacing the buffer would require data showing that the alternative system maintains solubility, pH, stability, dilution compatibility, and injectable quality.

Is fosphenytoin sodium available as a preservative-free injection?

The established single-dose injectable formulation uses a simple aqueous excipient system without a conventional antimicrobial preservative. Product-specific labeling should be verified before procurement.

Does fosphenytoin sodium require a 505(b)(2) application?

A conventional injectable that meets ANDA requirements can generally use the 505(j) pathway. A novel delivery system, materially different formulation, or new clinical use may require a 505(b)(2) strategy.

Could a prefilled fosphenytoin syringe receive patent protection?

Yes. Protection could focus on the syringe architecture, formulation-device compatibility, stability period, administration method, or an integrated emergency-use presentation, provided the claims satisfy patentability requirements.

What is the largest commercial barrier to a fosphenytoin sodium launch?

For a conventional generic, the largest barriers are sterile manufacturing reliability, hospital contracting, price erosion, and supply continuity rather than lack of therapeutic demand.

References

1. U.S. Food and Drug Administration. (2022). Cerebyx (fosphenytoin sodium) injection prescribing information. FDA.
2. U.S. Food and Drug Administration. (2022). Dilantin (phenytoin sodium) injection prescribing information. FDA.
3. U.S. Food and Drug Administration. (n.d.). ANDA submissions: Product-specific guidances for generic drug development. FDA.
4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.
5. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
6. U.S. Code. (2024). 21 U.S.C. § 355(j): Abbreviated applications for new drugs.
7. U.S. Food and Drug Administration. (n.d.). Drugs@FDA database. FDA.